Journal article
Identifying cytomegalovirus complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation
MK Yong, PU Cameron, M Slavin, CO Morrissey, K Bergin, A Spencer, D Ritchie, AC Cheng, A Samri, G Carcelain, B Autran, SR Lewin
Journal of Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2017
Abstract
Background. A simple test to identify recovery of CMV-specific T-cell immunity following hematopoietic stem cell transplantation (HSCT) could assist clinicians in managing CMV-related complications. Methods. In an observational, multicenter, prospective study of 94 HSCT recipients we evaluated CMV-specific T-cell immunity at baseline, 3, 6, 9, and 12 months after transplant using the Quantiferon-CMV, an enzyme-linked immunosorbent spot assay (ELISpot), and intracellular cytokine staining. Results. At 3 months after HSCT, participants who developed CMV disease (n = 8) compared with CMV reactivation (n = 26) or spontaneous viral control (n = 25) had significantly lower CD8+ T-cell production o..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council (NHMRC) Australia (GNT0607212), the Royal Australasian College of Physicians Priscilla Kincaid-Smith Award, and the French Embassy Scientific Mobility Program to M. K. Y. S. R. L. is an NHMRC of Australia practitioner fellow.